Abstract. This study examines the Poisson tumour control probability (TCP) γ 37 and D 37 parameters of a uniformly irradiated numerical tumour model using changes in tumour burden as a surrogate for treatment response information. An optimum dose D i for a tumour subvolume element V i is described that maximizes TCP as a function of fixed tumour integral dose ξ. TCP was calculated for spatially-varying clonogen density for a total 10 8 cells and radiosensitivity α with mean radiosensitivity in the range 0.4 -1.0 Gy -1 . A bivariate normal distribution is used to describe the radiosensitivity α and the linear term of the linear-quadratic (LQ) cell kill governed the changes in the regional tumour burden within sub-volumes V i . The optimum dose distribution, D i , for V i is obtained as a function of fixed tumour integral dose ξ. For a uniform dose delivery and for TCP = 37%, γ 37 and D 37 are described by the effective radiosensitivity α eff and the effective clonogen number N 0,eff , respectively. α eff is equivalent to differential dose changes in the number of clonogenic cells (tumour burden). The γ 37 values were found to be inversely correlated with variance of the probability density function of the α distribution. For the biologically optimum dose distribution, γ 37 was found to converge to the theoretical maximum limit and D 37 was found to reduce relative to that obtained for the uniform dose case. The TCP parameters γ 37 and D 37 could thus be useful in optimising individual radiation treatment doses even when tumour heterogeneity is taken into account.
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Introduction
With the availability of functional and molecular imaging modalities such as Positron Emission Tomography (PET), the acquisition and application of tumour specific, in vivo biological information to routine radiation treatment has become feasible. Biologically guided radiation treatment aims to achieve biological conformity of the dose distribution within tumour regions of higher recurrence risks to maximize the probability of local tumour control [1, 2] .
A validated biological response model can be used as an objective function for dose optimization of intensity modulated radiation treatment (IMRT), whereby the search for the optimum dose distribution can be directly based on treatment response to radiotherapy [3] . While experimental biological data are lacking, the effect on treatment response of intra-tumour biological heterogeneity has nevertheless been investigated in several theoretical modeling studies using tumour control probability (TCP) [4, 5, 6] . These studies showed that the variation of the radiosensitivity parameter α has a dominant influence on the TCP and dose response parameters.
In this study, the biological consequence of intra-tumour biological heterogeneity was studied under both uniform and biologically optimum (i.e. maximal TCP) dose distributions using the standard linear-quadratic (LQ) cell survival and mechanistic Poisson TCP models [3, 7] . These models were chosen for the current investigation due to their extensive application to radiation treatment response modeling and dose optimization studies. For uniform dose distribution, the steepness and the position of TCP curves were evaluated quantitatively with normalized dose gradient γ 37 and the dose required to achieve 37% of tumour control, D 37 . The normalized dose gradient γ is a relative measure of increase in TCP per given increment in dose. For Poisson TCP model, the steepest point of dose response curve is located at the 37% response level and, γ 37 is a function of number of (effective) clonogenic cells. Using the steepest part of the Poisson TCP curves and γ 37 and D 37 parameters, the aim was to evaluate quantitatively, the effect on the dose response curve of the biologically optimum dose distribution, in relation to the optimization criterion applied (TCP maximization) and also against the uniform dose cases as the reference. The relationship between tumour burden and γ 37 and D 37 parameters was investigated. The optimum dose distribution that maximizes TCP for a given fixed tumour integral dose ξ, was described and the gain in TCP from a biologically optimized dose distribution was quantified in terms of γ 37 and D 37 parameters.
Methods and materials

Poisson TCP and LQ cell survival models
It was assumed that a tumour is a parallel structure and is curable only if there is no surviving clonogen remaining after treatment [8] . For a discretized tumour model consisting of a group of M independent sub-volume elements (with the i-th element having volume V i ), the TCP is described by
where TCP M = exp(-N M ) is the probability of finding zero surviving clonogenic cells when the expected mean number of clonogenic cells is N M ≠ 0. The radiation response of tumour cells is described by the linear term of the LQ cell survival model [5] ; for element M with local radiosensitivity, α M , and surviving numberof cells,
where N M,0 was the initial number of clonogenic cells. The TCP curve was parameterized as a function of γ 37 and D 37 parameters [9] .
Optimum dose distribution
The optimum dose distribution that maximizes TCP was investigated using the Lagrange multiplier method. The objective was to find the maximum TCP under the constraints of fixed integral dose to a tumour. The objective function F was defined as the log of the TCP:
where N i,0 is the initial number of clonogenic cells, α i is the radiosensitivity and D i is the biologically optimum dose calculated for the i-th tumour element. The constraint of the fixed integral dose to a tumour is met if
, where ξ is the tumour integral dose. The constraint function φ is defined as: We define the auxiliary function G as:
where λ is the Lagrange multiplier. Taking the partial derivative of G with respect to D i , we can apply the multiplier condition: 7 , 3×10 7 , 3×10 7 and 2×10 7 cells, resulting in total 10 8 clonogenic cells. The radiosensitivity of human tumours is difficult to determine in vivo [10] . Currently no known molecular imaging modality can directly provide spatial intra-tumour radiosensitivity distribution in vivo [11] . With limited information on the true distribution of radiosensitivity, α was described by a randomly distributed bivariate normal distribution [12] , as follows: . With equal variance and zero co-variance terms, the probability density function provided a basic form of normally distributed α distributions that can be mapped on the clonogenic cell distribution. A 1-D Gaussian alpha distribution was applied to the LQ cell survival and Poisson TCP models of the same mathematical forms [6] . The variance parameters σ x 2 = σ y 2 = 10.0 and 11.0 were chosen to yield the coefficient of variation in surviving fraction at 2 Gy to be between 10 -15% [13] for α mean = 0.4 and less than 30% at α mean = 0.8 and were used with mean radiosensitivity α mean = 0.4 -1.0 Gy -1 . Ten series of p normal (x i , y j ) were generated for each variance parameter to calculate the corresponding TCPs.
Tumour model
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Results and discussion
Biologically optimum dose distribution
The equation for biologically optimum D i distribution was obtained as a function of fixed tumour integral dose ξ from equation (5) . 
TCP γ 37 and D 37 parameters for uniform and biologically optimum dose distribution
For a uniform dose delivered to the non-uniform model tumour, the TCP γ 37 and D 37 parameters were defined by γ 37 =lnN 0,eff ·e -1 and D 37 =e·γ 37 ·(α mean ) -1 respectively. N 0,eff is the effective clonogenic cell number and α eff is the effective radiosensitivity, which is the differential dose change in the number of clonogenic cells at TCP = 37%. N 0,eff is a function of α eff and D 37 at TCP = 37% . Figure 1 shows the variation of mean α eff ·(α mean ) -1 for the uniform dose delivery. Tables 1 and 2 For the biologically optimum dose distribution, γ 37,mean converges to the maximum theoretical limit. Negligible differences in γ 37,mean were found between σ x 2 = σ y 2 = 10.0 and 11.0. A similar observation was made for D 37,mean (0.5%) (cf. 4.5% for uniform dose case).
In this study, a range of α mean values have been considered up to 1.0 Gy -1 as an upper limit. For a tumour with a majority of clonogens consisting of a highly radiosensitive population (e.g. α mean = 1.0 Gy -1 ), the tumour control could be dominated by the small number of radioresistant sub-population of cells. If this were the primary cause of radiation treatment failure for a given tumour, the current dose optimization (dose redistribution) approach may enable more efficient use of radiation dose to control the regions of high resistance to achieve the optimum tumour control.
An earlier study by Yang and Xing [14] explored an IMRT dose optimization framework incorporating spatial biology distribution using LQ cell survival and Poisson TCP models. The current study investigated a similar question but with a different approach in that the dose prescription was derived as an implicit function of tumour integral dose. In the current approach, the intermediate step that was needed to correlate the reference voxel dose with a voxel dose in question is no longer required. This study also evaluated the effect of uniform and biologically optimised dose distributions using a plan quality indicator, the Poisson TCP at 37% of tumour control, instead of dose volume criteria [14] .
Further work is required to incorporate the effect on TCP of uncertainty in the radiosensitivity parameter estimation and to use the realistic (deliverable) dose model that results from biologically optimum dose prescription D i .
Conclusion
For a heterogeneous tumour treated with a uniform radiation dose, TCP = 37% can be adequately described with parameters γ 37 and D 37 analogous to those employed for a homogeneous tumour, by introducing an effective radiosensitivity α eff and an effective clonogen number N 0,eff . The parameter α eff is equivalent to differential dose changes in the number of clonogenic cells, which could potentially be determined experimentally. For a heterogeneous tumour treated with a biologically optimized dose distribution, on the other hand, γ 37 is maximized, while D 37 is reduced. These results suggest that the Poisson TCP parameters γ 37 and D 37 could be useful in optimizing individual radiation treatment doses. 
